Want to see HK:0690 full AI Analyst Report?
Top Page
Uni-Bio Science Group Ltd.
(0690)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$0.07
▼(-43.08% Downside)
Action:Upgraded
Date:09/09/26
The score is driven primarily by solid financial performance (sustained profitability, strong margins, and manageable leverage) and attractive valuation (low P/E and strong dividend yield). These positives are tempered by weaker technicals (price below longer-term moving averages and negative MACD) and a key fundamental risk from the sharp 2025 revenue decline and uneven cash conversion.
Positive Factors
Sustained Profitability
The shift from earlier losses to several years of positive earnings indicates a materially stronger operating base. High gross margins and mid-teens net margins provide capacity to fund commercialization, research, and expansion while supporting resilience over the next several quarters.
Negative Factors
Sharp Revenue Contraction
The steep 2025 revenue decline raises a fundamental question about demand durability and the resilience of the company’s commercialization model. If weaker sales persist, operating leverage could pressure earnings and reduce the resources available for product development and market expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Profitability
The shift from earlier losses to several years of positive earnings indicates a materially stronger operating base. High gross margins and mid-teens net margins provide capacity to fund commercialization, research, and expansion while supporting resilience over the next several quarters.
Read all positive factors
Uni-Bio Science Group Ltd. (0690) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$351.47M
Dividend Yield4.67%
Average Volume (3M)3.94M
Price to Earnings (P/E)8.3
Beta (1Y)>-0.01
Revenue Growth-6.75%
EPS Growth-47.06%
CountryHK
Employees543
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding5,971,228,000
10 Day Avg. Volume1,036,900
30 Day Avg. Volume3,939,493
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)1.66
Price to Sales (P/S)1.17
P/FCF Ratio18.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Uni-Bio Science Group Ltd. Business Overview & Revenue Model
Company Description
Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health condition...
How the Company Makes Money
The company makes money primarily by commercializing its biologic drug products, with revenue generally generated from the sale of finished pharmaceutical products (and, where applicable, related distribution/commercialization activities) into its...
Uni-Bio Science Group Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 549.77M | 586.21M | 552.98M | 484.72M | 440.32M | 353.40M |
| Gross Profit | 454.71M | 487.56M | 461.07M | 392.82M | 334.88M | 277.01M |
| EBITDA | 68.09M | 108.32M | 113.56M | 93.56M | 61.21M | 1.31M |
| Net Income | 48.54M | 93.33M | 82.77M | 70.88M | 38.51M | -19.59M |
Balance Sheet | ||||||
| Total Assets | 605.53M | 579.80M | 517.55M | 409.99M | 292.47M | 267.59M |
| Cash, Cash Equivalents and Short-Term Investments | 158.87M | 179.89M | 183.90M | 129.24M | 98.22M | 83.61M |
| Total Debt | 85.64M | 97.76M | 115.19M | 56.30M | 22.67M | 5.60M |
| Total Liabilities | 156.82M | 166.56M | 191.91M | 152.82M | 97.72M | 93.29M |
| Stockholders Equity | 448.71M | 413.25M | 325.64M | 257.17M | 194.75M | 174.31M |
Cash Flow | ||||||
| Free Cash Flow | -8.76M | 38.12M | 28.71M | 39.11M | 20.23M | 3.61M |
| Operating Cash Flow | 43.47M | 90.34M | 66.71M | 98.85M | 48.66M | 12.04M |
| Investing Cash Flow | -37.81M | 66.36M | -168.07M | -76.14M | -27.03M | 42.12M |
| Financing Cash Flow | -13.90M | -33.81M | 27.79M | 24.51M | 2.58M | 478.00K |
Uni-Bio Science Group Ltd. Technical Analysis
Neutral
0.13
Price Trends
0.07
Negative
0.08
Negative
0.09
Negative
Market Momentum
>-0.01
Negative
63.51
Neutral
51.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0690, the sentiment is Neutral. The current price of 0.13 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 63.51 is Neutral, neither overbought nor oversold. The STOCH value of 51.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0690.
Uni-Bio Science Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$351.47M | 8.27 | 11.26% | 4.67% | -6.75% | -47.06% | |
59 Neutral | HK$3.39B | 4.72 | 10.99% | ― | 1417.68% | 660.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$1.84B | 18.57 | 48.25% | ― | 88.38% | ― | |
46 Neutral | HK$650.01M | -3.33 | -7.32% | ― | ― | 51.71% | |
45 Neutral | HK$454.27M | -1.75 | -32.08% | ― | 215.14% | 40.49% | |
44 Neutral | HK$639.70M | -7.46 | 154.12% | ― | -55.22% | 57.76% |
* Healthcare Sector Average
HK:0690
Uni-Bio Science Group Ltd.
0.07
-0.09
-56.21%
HK:2137
Brii Biosciences Limited
0.93
-1.28
-57.92%
HK:6998
Genor Biopharma Holdings Limited
1.70
-3.11
-64.76%
HK:2181
Mabpharm Limited
0.45
-0.34
-42.95%
HK:6628
Transcenta Holding Limited
0.98
-4.35
-81.61%
HK:2496
Wuhan YZY Biopharma Co., Ltd. Class H
3.30
-2.20
-40.00%
Uni-Bio Science Group Ltd. Corporate Events
Uni-Bio Science Wins Strong Shareholder Backing for Executive Option Grants
Aug 19, 2026
Independent shareholders of Uni-Bio Science Group Ltd. have approved a series of share option grants to key executives at an extraordinary general meeting held on 19 August 2026. Four ordinary resolutions authorizing options over a total of 300 mi...
Uni-Bio Science Sets August Board Meeting to Approve Interim Results
Aug 14, 2026
Uni-Bio Science Group Limited has scheduled a board meeting for 26 August 2026 at its registered office to review and approve the interim financial results for the six months ended 30 June 2026. Following board approval, the company plans to publi...
Uni-Bio Science Flags Profit Drop as Tax and Pricing Pressures Bite
Aug 7, 2026
Uni-Bio Science Group Limited has warned that its net profit for the six months ended 30 June 2026 is expected to drop to about HK$30 million from HK$75.96 million a year earlier, citing higher value-added tax rates on biological products in China...
Uni-Bio Science to Seek Shareholder Approval for Large Executive Option Grant
Jul 29, 2026
Uni-Bio Science Group Limited has called an extraordinary general meeting for 19 August 2026 at its Hong Kong Science Park offices. The meeting will be open to registered shareholders, who may appoint proxies, with the share register closed from 1...
Uni-Bio Science Grants 300 Million Share Options to Senior Executives
Jun 24, 2026
Uni-Bio Science Group Ltd. has granted share options over 300 million shares to four senior executives, including its chairman, chief executive officer, chief operating officer and chief business officer, under its existing share option scheme. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.